Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
This study has been completed.
Sponsor:
Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier:
NCT00208026
First Posted: September 21, 2005
Last Update Posted: October 18, 2017
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Albert Yan, Children's Hospital of Philadelphia
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Netherton syndrome is a genetic condition that can result in abnormal skin functioning. People with this condition often have red and scaling skin; sparse or short hair; and problems with absorption of medicines or chemicals that are applied to the skin. If these chemicals are absorbed at a high level, they may cause health problems. Elidel (pimecrolimus) is a new medicine that is available as a cream. It has been shown to help improve the appearance of the skin in patients with another skin condition known as atopic dermatitis, and is approved by the United States (US) Food and Drug Administration for use in children with mild to moderate atopic dermatitis. The purpose of this study is to determine if Elidel is safe, to see whether the medication is absorbed through the skin, and to see if side effects are associated with its use in children with Netherton syndrome.
| Condition | Intervention | Phase |
|---|---|---|
| Netherton Syndrome | Drug: Pimecrolimus 1% Cream | Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | Exploratory Safety and Systemic Absorption of Elidel (Pimecrolimus) 1% Cream for the Treatment of Netherton Syndrome |
Resource links provided by NLM:
Genetics Home Reference related topics:
Netherton syndrome
Drug Information available for:
Pimecrolimus
Genetic and Rare Diseases Information Center resources:
Netherton Syndrome
Ichthyosis Linearis Circumflexa
Exfoliative Dermatitis
Tylosis
U.S. FDA Resources
Further study details as provided by Albert Yan, Children's Hospital of Philadelphia:
Primary Outcome Measures:
- Highest Peak Blood Concentration of Pimecrolimus Over All Study Visits [ Time Frame: Each visit up to 18 months ]At each scheduled visit, blood concentration of pimecrolimus were obtained. This value reflects the amount of pimecrolimus in the blood. This is measured directly from the blood and provides an estimate of the degree of absorption of the treatment medication through the skin into the blood. Analysis was performed as intent-to-treat with last value carried forward, but no data points were missing.
- Eczema Area and Severity Index (EASI) [ Time Frame: Each visit ]
- Netherton Area and Severity Assessment (NASA) [ Time Frame: Each visit ]
- Investigator's Global Evaluation of Disease (IGED) [ Time Frame: Each visit ]
- Pruritus Severity Assessment [ Time Frame: Each visit ]
- Transepidermal Water Loss [ Time Frame: Each visit ]
Secondary Outcome Measures:
- Complete Blood Count With Differential [ Time Frame: Each visit ]
- Blood Electrolytes and Fasting Glucose [ Time Frame: Each visit ]
- Blood Urea Nitrogen and Creatinine [ Time Frame: Each visit ]
- Liver Function Tests [ Time Frame: Each visit ]
| Enrollment: | 3 |
| Study Start Date: | September 2005 |
| Study Completion Date: | March 2008 |
| Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Pimecrolimus 1% Cream
Treatment with drug/Elidel. Single arm-open-label treatment arm. A Pilot Study of the Efficacy and Safety of Pimecrolimus Cream 1% for the Treatment of Netherton Syndrome:
|
Drug: Pimecrolimus 1% Cream
Open label single arm
Other Names:
|
Detailed Description:
Patients with Netherton syndrome, a rare genodermatosis, manifest a chronic, eczematous dermatitis with erythema and scaling that is often recalcitrant to conventional therapy with emollients and topical corticosteroids. These patients display an altered epidermal barrier with increased permeability to topical agents and are therefore susceptible to evaporative transepidermal water loss and infection. Topical therapy with the calcineurin inhibitors tacrolimus and pimecrolimus has been demonstrated to improve the skin integrity and the quality of life of patients with several chronic dermatoses, including atopic dermatitis. As a result of the underlying skin barrier dysfunction, however, the possibility of significant systemic absorption and resultant side effects is a concern when these agents are used in patients with Netherton syndrome. Experience with topical tacrolimus 0.1% ointment for patients with Netherton syndrome has demonstrated both marked efficacy as well as significant systemic absorption of the drug in this patient population. Use of topical pimecrolimus in patients with Netherton syndrome has not been reported to date. Investigation of the extent of systemic absorption and side effects will help to define the safety and efficacy profile of topical pimecrolimus in patients with Netherton syndrome.
Eligibility
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 2 Years to 18 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Clinical diagnosis of Netherton syndrome
- Normal laboratory values within 3 months prior to enrollment
- Signed written informed consent
- Willingness and ability to comply with the study requirements
- For women of childbearing age, negative urine pregnancy test at enrollment and then monthly thereafter; women of childbearing age who are not abstinent must use contraception.
Exclusion Criteria:
- Clinically significant physical examination or laboratory abnormalities
- Clinical evidence of liver disease or liver injury as documented by abnormal liver function tests
- Symptoms of a significant acute illness in the 30 week period preceding the start of treatment
- Patients with known serious adverse reactions or hypersensitivity to macrolides or calcineurin inhibitors or with known hypersensitivity to any of the ingredients of the study medication or history of adverse reactions to the anesthetic product used for blood draws
- Topical tacrolimus or Elidel within 2 weeks prior to dosing
- Systemic steroid, systemic tacrolimus, or any immunosuppressant within 1 month prior to dosing
- Phototherapy within 1 month prior to dosing
- Use of inhibitors of Cytochrome P450 3A4 (CYP3A4) iso-enzyme within 2 weeks prior to dosing
- Topical steroids or other topical therapy (except tacrolimus) may be used up to the day of 1st application of Elidel; however, treatment must be discontinued during the treatment period. Topical treatment of corticosteroids may resume immediately after the treatment period or in case an alert value has been exceeded and the Elidel treatment will be continued only on the face and neck.
- Participation in any clinical trials within 2 months prior to dosing
- History or clinical evidence of cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematologic, neurologic disease, or any disease other than Netherton syndrome, that may put the subject at undue risk. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs.
- History of presence of malignancy or lymphoproliferative disease
- Presence of any viral or fungal or untreated bacterial skin infection
- Known HIV positivity or active hepatitis B or C
- History of immunocompromise
- No vaccines containing live viruses are to be administered during the study period.
Contacts and Locations
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00208026
Locations
| United States, Pennsylvania | |
| Children's Hospital of Philadelphia | |
| Philadelphia, Pennsylvania, United States, 19104 | |
Sponsors and Collaborators
Children's Hospital of Philadelphia
Novartis Pharmaceuticals
Investigators
| Principal Investigator: | Albert C Yan, MD | Children's Hospital of Philadelphia |
More Information
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Albert Yan, Principal Investigator, Children's Hospital of Philadelphia |
| ClinicalTrials.gov Identifier: | NCT00208026 History of Changes |
| Other Study ID Numbers: |
2004-11-4063 |
| First Submitted: | September 13, 2005 |
| First Posted: | September 21, 2005 |
| Results First Submitted: | March 9, 2011 |
| Results First Posted: | December 12, 2014 |
| Last Update Posted: | October 18, 2017 |
| Last Verified: | October 2017 |
Additional relevant MeSH terms:
|
Syndrome Netherton Syndrome Disease Pathologic Processes Abnormalities, Multiple Congenital Abnormalities Ichthyosiform Erythroderma, Congenital Ichthyosis Skin Abnormalities Skin Diseases, Genetic Genetic Diseases, Inborn Infant, Newborn, Diseases Keratosis Skin Diseases Pimecrolimus |
Tacrolimus Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Dermatologic Agents Immunosuppressive Agents Immunologic Factors Calcineurin Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |